EuroCareFinderExplore healthcare across Europe
← Back to EuroCareFinder

Condition

Lipedema

Dermatology

Overview

Disorder of adipose tissue characterized by symmetric and bilateral enlargement of the lower extremities due to abnormal deposition of SUBCUTANEOUS FAT often in obese women. It is associated with HEMATOMA, pain and may progress to secondary LYMPHEDEMA which is known as lipolymphedema.

This information is general and should not be treated as medical advice. Always speak directly with a qualified healthcare professional before making decisions about treatment, diagnosis, procedures, medicines or care.

Quick facts about Lipedema

Topic type
Condition
Category
Dermatology
MeSH classification
C17.300.451

Preparing for an appointment about Lipedema

If you are speaking with a healthcare professional about Lipedema, it can help to prepare a few details in advance.

  • Write down your symptoms and when they started.
  • Bring details of any medicines, supplements or previous treatments.
  • Ask what tests or assessments may be needed.
  • Ask what treatment or management options may be suitable.
  • Ask when you should seek urgent medical help or follow-up care.

Finding care related to Lipedema

EuroCareFinder helps patients explore clinics and healthcare providers across Europe. Some topics link directly to services offered by clinics, while others may be connected through related specialties, treatments or procedures.

Explore clinics across Europe

Browse the wider EuroCareFinder healthcare network using the interactive map.

Clinics related to Lipedema

No clinics are currently linked directly to Lipedema on EuroCareFinder.

As more clinics add detailed services, related providers may appear here.

Related topics

Explore healthcare providers

Use EuroCareFinder to browse clinics by country, specialty and available services.

Source: Medical Subject Headings (MeSH), produced by the U.S. National Library of Medicine. EuroCareFinder is not endorsed by the National Library of Medicine. MeSH version: 2026.